PHASE II STUDY OF BIWEEKLY IRINOTECAN PLUS BEVACIZUMAB IN HEAVILY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0

作者：

Cardona, Andres F. ^{[1
]}

Arrieta, Oscar ^{[2
,3
]}

Cuello, Mauricio ^{[4
]}

Corrales, Luis ^{[5
]}

Vargas, Carlos ^{[1
]}

Martin, Claudio ^{[6
]}

Carranza, Hernan ^{[1
]}

Otero, Jorge M. ^{[1
]}

Katherine Rodriguez, July ^{[7
]}

Mas, Luis ^{[8
]}

Archila, Pilar ^{[7
]}

Bramuglia, Guillermo ^{[9
]}

Pastran, Zulay ^{[10
]}

Curcio, Elizabeth ^{[11
]}

Rojas, Leonardo ^{[2
,3
]}

Bernal, Laura ^{[1
]}

Campos Parra, Alma D. ^{[2
,3
]}

Giannikopoulos, Petros ^{[12
]}

Rosell, Rafael ^{[13
]}

机构：

[1] Fdn Santa Fe Bogota, Clin & Translat Oncol Grp, Bogota, Colombia

[2] Inst Nacl Cancerol INCAN, Thorac Oncol Clin, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol INCAN, Lab Expt Oncol, Mexico City, DF, Mexico

[4] Hosp Clin, Udelar, Uruguay

[5] Hosp San Juan De Dios Ccss, San Jose, Costa Rica

[6] Alexander Fleming, Oncol, Buenos Aires, DF, Argentina

[7] Fdn Clin & Appl Canc Res Ficmac, Bogota, Colombia

[8] Inst Enfermedades Neoplas, Lima, Peru

[9] Fdn Invest, Buenos Aires, DF, Argentina

[10] Policlin Metropolitana, Caracas, Venezuela

[11] Grp Trabajo Oncol Med, Maracaibo, Venezuela

[12] Canc Therapeut Innovat Grp, New York, NY USA

[13] Catalan Inst Oncol, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

Lung cancer; irinotecan; bevacizumab; response; progression free survival;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.10-043

引用

页码：S881 / S882

页数：2